ADMA Biologics, Inc. (ADMA)
9.72
-0.21
(-2.11%)
USD |
NASDAQ |
Oct 02, 16:00
9.72
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Price : 9.72 for Oct. 2, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 02, 2026 | 10.02 | 10.28 | 9.68 | 9.72 | 2.793M |
| Oct 01, 2026 | 10.07 | 10.26 | 9.905 | 9.93 | 3.970M |
| Sep 30, 2026 | 9.98 | 10.14 | 9.795 | 10.03 | 2.699M |
| Sep 29, 2026 | 10.04 | 10.18 | 9.894 | 9.96 | 3.458M |
| Sep 28, 2026 | 9.38 | 10.17 | 9.25 | 10.12 | 3.568M |
| Sep 25, 2026 | 9.55 | 9.625 | 9.23 | 9.38 | 3.567M |
| Sep 24, 2026 | 9.67 | 9.825 | 9.37 | 9.52 | 2.587M |
| Sep 23, 2026 | 9.81 | 9.84 | 9.43 | 9.70 | 2.595M |
| Sep 22, 2026 | 9.535 | 9.835 | 9.45 | 9.81 | 2.738M |
| Sep 21, 2026 | 9.185 | 9.54 | 9.10 | 9.505 | 2.859M |
| Sep 18, 2026 | 8.92 | 9.13 | 8.81 | 9.11 | 11.40M |
| Sep 17, 2026 | 9.00 | 9.05 | 8.875 | 8.95 | 2.132M |
| Sep 16, 2026 | 8.59 | 8.98 | 8.54 | 8.90 | 2.767M |
| Sep 15, 2026 | 9.08 | 9.13 | 8.55 | 8.61 | 3.589M |
| Sep 14, 2026 | 9.34 | 9.375 | 9.065 | 9.14 | 3.067M |
| Sep 11, 2026 | 9.44 | 9.50 | 9.195 | 9.23 | 2.267M |
| Sep 10, 2026 | 9.39 | 9.50 | 9.33 | 9.39 | 2.831M |
| Sep 09, 2026 | 9.47 | 9.506 | 9.32 | 9.45 | 2.383M |
| Sep 08, 2026 | 9.51 | 9.65 | 9.41 | 9.54 | 1.993M |
| Sep 04, 2026 | 9.43 | 9.62 | 9.39 | 9.62 | 1.406M |
| Sep 03, 2026 | 9.52 | 9.60 | 9.345 | 9.58 | 1.326M |
| Sep 02, 2026 | 9.34 | 9.63 | 9.320 | 9.51 | 1.990M |
| Sep 01, 2026 | 9.38 | 9.505 | 9.29 | 9.33 | 1.756M |
| Aug 31, 2026 | 9.33 | 9.475 | 9.22 | 9.39 | 1.756M |
| Aug 28, 2026 | 9.46 | 9.51 | 9.34 | 9.34 | 1.838M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Vericel Corp. | 40.15 |
| BioMarin Pharmaceutical, Inc. | 57.18 |
| Emergent BioSolutions, Inc. | 6.33 |
| Exelixis, Inc. | 58.39 |
| Akebia Therapeutics, Inc. | 0.865 |
Price Related Metrics
| PE Ratio | 13.80 |
| PS Ratio | 4.548 |
| Price to Book Value | 5.366 |
| Price to Free Cash Flow | 20.05 |
| Earnings Yield | 7.25% |
| Market Cap | 2.190B |
| Operating PE Ratio | 10.76 |
| Normalized PE Ratio | 13.68 |